|Wednesday, November 22, 2017||
Click the diagram above
to view the XBL Navigator.
XBL Awarded NIDA/NIH Contract as Analytical Services Center for Medications Development Program
Plainsboro, New Jersey, October 11, 2013 - XenoBiotic Laboratories (XBL) is pleased to announce that it has been recently awarded a five year contract from the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Department of Health and Human Services (HHS)*. This research and development contract will provide bioanalytical chemistry resources to support NIDA’s medications development program. This contract will also provide a centralized bioanalytical facility to carry out quantitative and/or qualitative assays for a variety of compounds, including but not limited to, new medications and/or their metabolites, abused drugs/metabolites, potential concomitant medications/compounds and molecular biomarkers (small molecules, peptides and proteins).
XBL was selected following an extensive competitive review process, based in part on the company’s past history, recommendations, scientific capabilities, compliance to GLP regulations and our extensive knowledge of Bioanalysis and metabolism as it pertains to drug development.
As part of its preparation to win this contract, XBL conducted a risk assessment for scientific, instrumentation, regulations, and all aspects of operations including emergency readiness, IT and data integrity. Indeed, one of the first task requirements under this contract is to provide an IT security plan, risk assessment and FIPS 199 assessment, which is well underway.
“We are pleased to be awarded this 5 year contract from NIDA/NIH”, commented Dr. Jinn Wu, President and CEO of XenoBiotic Laboratories, “and for XBL’s reputation of providing high quality services in Bioanalysis and DMPK to be recognized by the NIH”.
Since 1987, XBL has been providing clinical and non-clinical bioanalytical and ADME/DMPK (in vitro and in vivo) services to the pharmaceutical, animal health and agrochemical industries. As part of its commitment to this NIDA/NIH program and our Pharma directed programs, XBL continues to enhance its core services, as well as its operational infrastructure to adhere to the strictest data security and reporting requirements. XBL facilities in Plainsboro, NJ (www.xbl.com) and in Nanjing, China (www.xbl-china.com) operate to GLP standards, are licensed for radioisotopes, and are AAALAC accredited for animal research.
For further information, contact:
Dennis P. Heller, Ph.D., VP Pharmaceutical Development, email@example.com or inquire at www.xbl.com
XenoBiotic Laboratories, Inc., 609 799-2295 or 888 XENO-880 (936-6880)
*This project has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271201300043C.
|©2005-2017, XenoBiotic Laboratories, Inc. All rights reserved.
Website created by Princeton Internet Group (PING)